Gufic Biosciences Assigned ESG Rating of 68.2/100 by SES ESG Research
Gufic Biosciences Limited received an ESG rating of 68.2/100 (Category: Medium) for FY 2024-25 from SES ESG Research. SES, a SEBI registered provider, assigned the rating independently based on public information. The company received the report on December 09, 2025.
The ESG rating is an informational disclosure and does not immediately impact the company's operations, financials, or market position. While ESG ratings are increasingly important, a 'Medium' category rating from an independent assessment, without prior engagement, suggests a low immediate impact.
The announcement is a neutral disclosure of an ESG rating assigned by a third-party agency. It does not contain any specific financial performance indicators or significant business developments that would warrant a positive or negative sentiment.
Gufic Biosciences Limited has received an Environmental, Social, and Governance (ESG) rating of 68.2 out of 100 from SES ESG Research Private Limited. The rating, categorized as 'Medium', is for the Financial Year 2024-25 and was assigned by SES, a SEBI Registered Category – II ESG Ratings Provider. The company received the report on December 09, 2025. It is important to note that Gufic Biosciences did not engage SES for this rating; SES independently assigned it based on publicly available information.
This disclosure is made pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.